Does Medicare Cover Imvexxy? 2026 Coverage, Costs, and Denial Steps

The HRT Index earns commission from some links on this site. That never changes what we verify or what we publish. Our affiliate disclosure.

Does Medicare cover Imvexxy? Sometimes. A stand-alone Part D plan or Medicare Advantage drug plan may cover it, but coverage, tier, prior authorization, and price are plan-specific. Original Medicare Parts A and B do not cover a routine pharmacy fill. If your plan says no, the denial reason determines the fastest fix.

Best for: A woman who has Medicare, has an Imvexxy prescription or refill coming up, and needs to know whether to use the plan, request an exception, challenge an “excluded” answer, or compare the separate Medicare coupon.

Not for you if: You are still deciding whether vaginal estrogen is clinically right for you; start with our vaginal estrogen guide. If you have any bleeding after menopause, stop here and contact a clinician. The current Imvexxy label lists undiagnosed abnormal genital bleeding as a contraindication and calls for evaluation of persistent or recurring postmenopausal bleeding.^[1]

What is the 60-second answer on Medicare coverage for Imvexxy?

There are three Medicare coverage doors: covered, off-formulary, or described by the plan as excluded or “not a Part D drug.” A fourth situation—having Original Medicare without drug coverage—is an enrollment problem rather than a denial. Do not accept a vague “not covered” until the plan tells you which one it means.

What your plan or pharmacy told you	What it means	What you do next
“It is covered, but your cost is $X”	Door 1: Imvexxy is on your formulary, possibly with prior authorization, a quantity limit, a deductible, or a higher tier	Confirm the exact pack and billed NDC. Request prior authorization, a restriction exception, or—where the plan permits it—a tiering exception
“It is not on our formulary”	Door 2: Your plan does not list the product, but Part D may cover it after a formulary exception	Ask your prescriber to submit the plan’s exception request and supporting statement
“It is excluded” or “not a Part D drug”	Door 3: The plan is making a coverage-classification decision	Request a formal written coverage determination. CMS clarified in 2018 that drugs labeled for moderate-to-severe dyspareunia due to menopause are not excluded when used consistently with that labeling; an unfavorable determination carries appeal rights[2][4]
“You only have Original Medicare”	Parts A and B do not include routine outpatient prescription coverage	Check whether you have separate Part D, an MA-PD plan, or an enrollment opportunity. This is not fixed with a drug exception

A formulary is the plan’s drug list. A tier is the pricing level. Prior authorization means the drug may be covered after the prescriber supplies information. A coverage determination is the formal plan decision you need when a phone representative’s answer is too vague to act on.

Why can’t any website tell you your exact Imvexxy copay?

We cannot tell you your exact Imvexxy copay from this page. No honest national article can, because your result changes with the plan, exact package, pharmacy network, deductible, benefit stage, and live claim. We would rather lose your click than invent a clean number that falls apart at the counter.

We also cannot make a plan pay. A telehealth visit, discount card, and manufacturer program cannot override a Part D formulary decision. A prescriber can submit prior-authorization or exception evidence, and you can force a vague denial into a written determination with appeal instructions. That is the leverage this page gives you.

So here is the trade. How much you will pay today requires a live plan or pharmacy quote. Why the claim failed and which lever fits it can be resolved now.

That is worth more than a coupon you cannot use.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Before you go further

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

→ Match your situation to the right path — free, about 90 seconds, no account.

Does Medicare cover Imvexxy in 2026?

A stand-alone Part D plan or a Medicare Advantage plan with prescription coverage can cover Imvexxy, but no national rule requires every plan to list it. Current 2026 carrier documents produce opposite answers: one UnitedHealthcare notice makes Imvexxy non-formulary within its stated plan scope, while a specific Humana group formulary lists the maintenance pack on Tier 3 with prior authorization.

UnitedHealthcare’s December 1, 2025 provider notice says that, starting January 1, 2026, Imvexxy and Femring became non-formulary for the notice’s stated scope: UnitedHealthcare Individual and select Employer Group Medicare Advantage plans—including non-SNPs, D-SNPs, and C-SNPs—and stand-alone Part D plans. It names estradiol, Estring, Premarin, and Yuvafem as covered alternatives, while warning that alternative coverage still varies by formulary.^[5]

Humana’s 2026 Group Plus Formulary 26800 points the other way. Its “Commonly Prescribed Medications List”—which is explicitly not the complete formulary—lists Imvexxy Maintenance Pack, Tier 3, prior authorization. On the same page, estradiol vaginal cream and Yuvafem appear on Tier 1, Premarin Vaginal Cream on Tier 2, and Estring on Tier 3.^[6]

Same drug. Same year. Opposite answers.

That is exactly why this page will not tell you Medicare “always,” “never,” or “typically” covers Imvexxy without defining the data behind the word. Your plan is not a national average. The only answer that pays at the counter is the answer attached to your exact plan, exact package, exact pharmacy, and exact claim date.

Why do Medicare plans give opposite answers on Imvexxy?

Plans can make different formulary choices, but a categorical statement that Imvexxy is barred from Part D because it treats painful sex deserves a written challenge. The statute excludes drugs when used for sexual or erectile dysfunction unless used for another FDA-approved condition, while CMS later clarified that drugs labeled for moderate-to-severe dyspareunia due to menopause are not excluded when used consistently with that labeling. A plan may still leave Imvexxy off its formulary; that is a different decision.

This distinction is the load-bearing fact on the page.

What the statute says

The Part D definition of a covered drug excludes a drug when used for the treatment of sexual or erectile dysfunction unless it is used for another FDA-approved condition.^[3]

Read in isolation, that language can steer a representative or claim system toward the wrong conclusion about a drug whose indication mentions painful sex.

What the Imvexxy label says

The current FDA prescribing information states one indication: treatment of moderate-to-severe dyspareunia—a symptom of vulvar and vaginal atrophy—due to menopause. The labeled schedule is one vaginal insert daily for two weeks, followed by one insert twice weekly.^[1]

What CMS clarified in 2018

On May 10, 2018, the International Society for the Study of Women’s Sexual Health announced a CMS clarification stating that drugs for moderate-to-severe dyspareunia due to menopause are “not excluded from Medicare Part D coverage” when used consistently with that labeling. ISSWSH credited work with The North American Menopause Society and ACOG.^[2]

We did not locate the underlying CMS memo itself. We are not going to pretend we read it. We are relying on the dated medical-society announcement for the substance of the clarification and on current CMS pages for the formal coverage-determination, exception, and appeal process.

Both halves of the answer matter:

• Part D is allowed to cover labeled Imvexxy use. A blanket “painful sex means Medicare is forbidden to pay” conflicts with the reported CMS clarification.
• A plan is not forced to place Imvexxy on its formulary. It can still prefer another covered product, require prior authorization, or deny a formulary exception under its rules.

So Door 3 is not “appeals are useless.” Door 3 means you may be fighting a classification error instead of an ordinary formulary denial. Get it in writing. CMS defines a coverage determination broadly enough to include payment for a drug the member believes may be covered, the member’s cost, quantity limits, step therapy, prior authorization, and formulary or tiering exceptions. An unfavorable determination must include what you need to request redetermination.^[4]

That one correction saves you from doing the most expensive thing in Medicare: accepting a phone answer that never became an appealable decision.

Which Imvexxy Medicare coverage path are you in?

You can identify your route with four facts: your drug-coverage type, exact Imvexxy pack, the plan’s stated reason, and the result of a live pharmacy claim. This worksheet does not need your Medicare number, member ID, date of birth, diagnosis, or any other identifying information.

Imvexxy Medicare Route Checker

Write the answers on paper or print this section.

Question 1: What drug coverage do you have?

• Stand-alone Part D plan
• Medicare Advantage plan with drug coverage
• Original Medicare Parts A and B only
• Not sure

Question 2: What exact prescription is being billed?

• 4 mcg, 18-count starter pack
• 4 mcg, 8-count maintenance pack
• 10 mcg, 18-count starter pack
• 10 mcg, 8-count maintenance pack
• Not sure—ask the pharmacy for the strength, quantity, days’ supply, and 11-digit NDC

Question 3: Which exact phrase did the plan use?

• Covered, but prior authorization or another restriction applies
• Covered, but the price is high
• Non-formulary / not on the drug list
• Excluded / not a Part D drug
• Product not found / invalid NDC
• No clear answer

Question 4: What did a live pharmacy claim return?

Ask for the billed NDC, quantity, days’ supply, plan-paid amount, your amount, and rejection code. A formulary website is useful; a live claim is the transaction your next step must solve.

Your result	Your next request	What must happen before you move on
Door 1: covered with a restriction	Prior authorization or a request to waive step therapy/quantity limits; a tiering exception only when eligible under the plan	Prescriber sends the supporting information; confirm the plan received it
Door 1: covered but expensive	Ask whether deductible, tier, non-preferred pharmacy, or benefit stage caused the amount; compare the separate Medicare coupon only after obtaining its live price	Write down the plan price and what counts toward TrOOP
Door 2: non-formulary	Formulary exception with a prescriber supporting statement	The plan’s 72-hour or 24-hour exception clock starts only after it receives that statement[7]
Door 3: excluded / not a Part D drug	Formal written coverage determination citing the labeled indication and reported 2018 CMS clarification; appeal an unfavorable determination	Do not let “excluded” remain an unrecorded phone comment
Product not found / invalid NDC	Pharmacy and plan check the exact billed NDC and both public Imvexxy code families	Confirm the package, quantity, days’ supply, and NDC all match
Original Medicare only	Check Part D/MA-PD status and enrollment options with Medicare or SHIP	A prescriber exception cannot create drug coverage you do not have

→ Use this route checker first. It gives you a cleaner next step than calling the plan and asking the same broad question again.

What should you ask your Medicare plan and pharmacy?

One plan call and one pharmacy call usually reveal more than another hour of searching. The most important question is not “Is Imvexxy covered?” It is “What exact decision did you make on this exact package and NDC, and how do I get that decision in writing?”

Ask the plan these six questions:

1. 1. “Is Imvexxy on my current 2026 formulary? Please check 4 mcg and 10 mcg, and the 18-count starter and 8-count maintenance packs.”
2. 2. “What tier is my exact pack on, and does my deductible apply?”
3. 3. “Does it require prior authorization, step therapy, or a quantity limit?”
4. 4. “If it is not covered, is it non-formulary, or are you classifying it as excluded or not a Part D drug?”
5. 5. “How do I request a formal written coverage determination for that decision?”
6. 6. “What form, fax number, portal, and prescriber supporting statement do you require for an exception?”

Ask the pharmacy:

“Please run a live claim and read me the 11-digit NDC, strength, quantity, days’ supply, my price, the plan-paid amount, and the full rejection code. Is this pharmacy preferred under my plan? Does the plan recognize a different current package code for the same Imvexxy pack?”

Write down the representative’s name, reference number, date, and time. If the answer changes later, that record becomes your map back to the decision.

What does the 2026 exact-NDC data show?

Within Q1Medicare’s July 2026 exact-NDC index, each displayed Imvexxy package appeared on far fewer formulary listings than generic estradiol vaginal inserts or generic estradiol cream. That is a useful comparison of listing breadth, not a national coverage rate, a count of women covered, a price, or evidence that another product is clinically interchangeable.

We assembled the rows below from the same source format and the same month so the comparison is reproducible. The Q1Medicare finder was configured to ZIP code 33142 when checked. Its counts are best read as a relative index inside that dataset, not as a promise about any local plan.^[8]

Exact product row in the July 2026 index	Source-displayed package	Stand-alone Part D listings	Medicare Advantage drug-plan listings
Imvexxy 10 mcg maintenance pack, NDC 68308-0748-08	8 units	1	37
Imvexxy 10 mcg starter pack, NDC 68308-0748-18	18 units	1	37
Imvexxy 4 mcg maintenance pack, NDC 68308-0747-08	24 units in the index	1	37
Imvexxy 4 mcg starter pack, NDC 68308-0747-18	18 units	1	37
Generic estradiol 10 mcg vaginal insert, NDC 00093-3223-08	8 inserts	32	292
Yuvafem 10 mcg vaginal insert	8 inserts	31	282
Generic estradiol vaginal cream 0.01%	42.5 g	35	295
Premarin Vaginal Cream 0.625 mg/g	1 tube	28	240
Estring 7.5 mcg/day vaginal ring	1 ring	18	84
Brand Estrace vaginal cream	42.5 g	0	4

Our calculation: generic estradiol 10 mcg vaginal inserts appeared on 32 times as many stand-alone Part D listings and about 7.9 times as many Medicare Advantage drug-plan listings as one displayed Imvexxy pack. Generic estradiol cream appeared on 35 times and about 8.0 times as many, respectively.

That does not tell your prescriber what you should use. It tells you what kind of insurance fight you are walking into. Your plan did not decide your symptoms do not count; it made a formulary decision about a specific package.

The brand-versus-generic cream rows are the cleanest signal in the table: brand Estrace appears on 0 stand-alone and 4 Medicare Advantage listings, while generic estradiol cream appears on 35 and 295. That pattern is consistent with strong generic formulary preference. It does not prove why any one plan made its decision.

The source itself contains a discrepancy—and that matters

The Q1Medicare row displays the 4 mcg maintenance pack as 24 units. The current FDA label says Imvexxy maintenance cartons contain 8 inserts, while starter cartons contain 18.^[1]

We are leaving that mismatch visible instead of silently “fixing” the source. It proves why a third-party formulary row should never outrank the current label and the live pharmacy claim. If your plan search shows a quantity that does not match the prescription in your hand, stop and verify the NDC before anyone calls the drug uncovered.

Why must you check the Imvexxy pack and NDC—not just the name?

Imvexxy comes in two strengths and two labeled carton sizes, and coverage systems adjudicate the billed package code rather than the brand name alone. Public drug records also show two Imvexxy NDC families. That does not prove an NDC mismatch caused your denial, but it gives the pharmacy and plan a concrete error to rule out.

The four labeled cartons

Strength and carton	Labeled schedule	Approximate use
4 mcg, 18-count starter	One insert daily for 14 days, then twice weekly	The labeled initiation pack
10 mcg, 18-count starter	One insert daily for 14 days, then twice weekly	The labeled initiation pack
4 mcg, 8-count maintenance	One insert twice weekly, such as Monday and Thursday	28 days at the labeled schedule
10 mcg, 8-count maintenance	One insert twice weekly, such as Monday and Thursday	28 days at the labeled schedule

At the maintenance schedule, eight inserts cover 28 days. That is about 13 maintenance packs per year if treatment continues without interruption. A quantity limit of 8 per 28 days mirrors the label; a different limit deserves a pack-and-days-supply check before anyone assumes it is a medical restriction.

The two public code families

The Mayne-labeled DailyMed record lists these carton NDCs:^[1]

• 4 mcg maintenance: 50261-104-08
• 4 mcg starter: 50261-104-18
• 10 mcg maintenance: 50261-110-08
• 10 mcg starter: 50261-110-18

A separate public DailyMed record and the Q1Medicare index display the 68308 family, including 68308-0747-08/-18 and 68308-0748-08/-18.^[8][9]

The correct practical conclusion is narrow: ask which 11-digit NDC the pharmacy is billing and which NDC the plan is searching. Do not let a representative call Imvexxy discontinued, uncovered, or invalid until the package, quantity, days’ supply, and code have all been reconciled.

How much does Imvexxy cost with Medicare in 2026?

Your exact Medicare price can only come from your plan or a live pharmacy claim. In 2026, a Part D plan may have a deductible up to $615; under the standard benefit, members generally pay 25% after the deductible until covered-drug out-of-pocket spending reaches $2,100, then pay $0 for covered Part D drugs for the rest of the calendar year. Actual plans may use tiered copays or coinsurance.^[10]

The 2026 Part D structure

Part D stage	What Medicare says in 2026	What it means for Imvexxy
Deductible	No plan deductible can exceed $615; some plans have no deductible	A covered brand drug can still feel “uncovered” early in the year if you are paying through the deductible
Initial coverage	Under the standard benefit, you generally pay 25% for covered generic and brand drugs after the deductible	Your actual plan may apply tiered copays or coinsurance; get the live claim amount
Catastrophic coverage	After $2,100 in out-of-pocket spending on covered Part D drugs, you pay $0 for covered Part D drugs for the rest of the calendar year	Spending outside the benefit generally does not move you toward this line
Medicare Prescription Payment Plan	Spreads plan-covered out-of-pocket drug costs across the calendar year	It changes timing, not the total price[10]

“Covered” and “affordable” are two different questions. A Tier 3 listing with prior authorization can still produce a large amount because the deductible applies, the plan uses coinsurance, or the pharmacy is outside the preferred network.

Ask four separate questions:

1. 1. Is the exact pack covered?
2. 2. What restriction applies?
3. 3. What will this fill cost at this pharmacy today?
4. 4. How much of that payment counts toward my 2026 Part D out-of-pocket total?

What are current Imvexxy cash prices?

Cash-price websites disagree by more than $100 on the same 8-insert maintenance pack. That disagreement is the proof: “the cash price” is not one number. Package, strength, ZIP code, pharmacy, discount contract, and date must travel with every figure.

Source and date checked	4 mcg maintenance, 8 inserts	10 mcg maintenance, 8 inserts	Starter pack, 18 inserts	What the figure is—and is not
SingleCare article updated Aug. 6, 2026; price examples tied to ZIP 23666	$319 benchmark; $184 SingleCare example at Kroger	Source article presents one maintenance benchmark rather than a strength-specific split	$650 benchmark; $428 SingleCare example at Kroger	Dynamic retail and coupon examples, not Medicare prices or guarantees[11]
Drugs.com price guide checked Aug. 28, 2026	$229.07–$234.38	$218.54–$229.07	4 mcg: $505.52–$515.78; 10 mcg: $481.83–$505.52	Cash guide ranges; the source says variables can prevent a guarantee[12]

For an 8-insert maintenance pack, the SingleCare benchmark and the lowest Drugs.com 10 mcg figure differ by $100.46. That is not a rounding error. It is why a page that prints one national “Imvexxy cash price” without a date and source is manufacturing certainty.

Do not compare a discount-card number with your plan copay until you know what you give up by paying outside Part D. An outside discount may be cheaper today and more expensive across the calendar year if the plan payment would have helped you reach the $2,100 cap.

Can you use the regular Imvexxy savings card with Medicare?

No. The current standard Imvexxy copay card is limited to eligible commercially insured patients whose plan covers the prescription at the time of the fill. It excludes Medicare, Medicare Advantage, Part D, Medigap, Medicaid, TRICARE, cash-paying patients, and even certain Medicare-eligible people on employer or retiree prescription benefits.

The current official card does not promise a $35 copay. It says out-of-pocket costs vary, maximum limits apply, and the patient must satisfy any applicable deductible and prior-authorization requirements. The offer expires December 31, 2026, and Mayne Pharma may amend or end it without notice.^[13]

That corrects three traps you will still see online:

• Turning 65 by itself is not the card rule; Medicare enrollment, government coverage, and Medicare-eligible employer or retiree coverage are the relevant exclusions.
• Commercial insurance is not enough; the plan must cover the valid Imvexxy prescription at the fill.
• Uninsured and cash-paying patients are not eligible for the standard card.

If the card stopped working, ask the pharmacy for the rejection message. The right explanation may be Medicare eligibility, plan noncoverage, prior authorization, deductible requirements, an invalid Other Coverage Code, expiration, or another term—not simply your birthday.

How does the separate Imvexxy Medicare coupon work?

Mayne Pharma runs a different Imvexxy Medicare Part D Alternative Coupon Program for eligible Part D and Medicare Advantage drug-plan members. It may apply when the plan does not cover Imvexxy or when the plan’s out-of-pocket amount exceeds a pack-specific threshold. Those thresholds determine whether you may qualify; they are not guaranteed prices.

Here is the official threshold table, checked August 28, 2026:^[14]

Prescribed quantity	Program applies when the plan does not cover, or your plan out-of-pocket amount is…	What the number means
18-count starter pack	More than $50	Eligibility trigger—not a promised $50 price
8-count maintenance pack, one month	More than $50	Eligibility trigger—not a promised $50 price
16-count maintenance quantity, two months	More than $100	Eligibility trigger—not a promised $100 price
24-count maintenance quantity, three months	More than $150	Eligibility trigger—not a promised $150 price

The final price is the amount the program and participating pharmacy quote after eligibility and program limits are applied. Do not enroll based on the threshold alone.

What you agree to when you use it

For the rest of the calendar year, you agree to:

• stop purchasing Imvexxy through your Medicare Part D or Medicare Advantage drug benefit, even if your benefits change;
• notify the prescription plan using the program’s opt-out letter;
• not seek reimbursement through the plan, an HSA, an FSA, or another healthcare reimbursement account;
• not seek true out-of-pocket credit for the Imvexxy purchases;
• use a participating U.S. retail pharmacy and remain within reimbursement limits; and
• not combine the program with another coupon, free trial, discount card, or offer.^[14]

The opt-out letter asks for your name, date of birth, prescription plan, and membership ID, and states that purchases will not count toward TrOOP.^[15] The enrollment form also says Mayne and its vendor, InfinityRx, store personal and medical information for program administration; marketing consent is presented separately and is not a condition of purchase.^[14]

This is not a casual coupon code. It is a rest-of-calendar-year benefit decision for one drug.

→ Read the official Imvexxy Medicare coupon terms before enrolling — official program link; The HRT Index earns nothing from it.

What does the Medicare coupon cost you beyond the quoted price?

Imvexxy purchases made through the alternative coupon do not count toward the 2026 Part D out-of-pocket cap. That trade-off may be small when your plan was never paying for Imvexxy and you are nowhere near the cap. It may be expensive when covered prescriptions are already pushing you toward $2,100 or when an appeal could put Imvexxy back inside the benefit.

This is the damaging admission the program comparison needs.

The coupon may still be the cleanest practical route when:

• your plan is not covering Imvexxy after you have confirmed the reason;
• you have the program’s actual final price, not just the eligibility threshold;
• you do not expect Imvexxy spending to count toward the cap under your current plan decision; and
• the savings today outweigh the value of preserving the plan route for the rest of the year.

Slow down before enrolling when:

• Imvexxy is covered but expensive because you are still in the deductible;
• you take other costly covered drugs and expect to approach the $2,100 cap;
• a prior authorization, formulary exception, or classification appeal is still unresolved;
• you are early in the calendar year and would be giving up the plan route for many months; or
• the program has not yet told you the actual amount you will pay.

Run the real coupon math

Do not compare the plan price with “$50.” The official $50, $100, and $150 figures are qualification thresholds.

Fill in these numbers:

Your number	Where to get it
A. Plan price for the next fill: $_____	Live pharmacy claim or plan quote for the exact pack
B. Does A count toward TrOOP? Yes / No / Not sure	Plan or Explanation of Benefits
C. Alternative-coupon final price for the same quantity: $_____	Program or participating pharmacy after eligibility review
D. Fills remaining through Dec. 31: _____	Your prescribed schedule and refill date
E. Part D out-of-pocket spending so far: $_____	Current Explanation of Benefits
F. Expected spending on other covered Part D drugs: $_____	Your medication list and plan estimates

Then compare:

• Plan route before benefit-stage changes: A × D
• Coupon route: C × D
• Immediate difference: (A − C) × D
• Credit at risk: the portion of A × D that would have counted toward TrOOP
• Calendar-year question: Would removing that credit delay or prevent you from reaching $2,100?

This worksheet is deliberately not a recommendation. It forces the hidden cost into the same frame as the visible discount.

If your plan currently pays nothing and the outside purchase already would not count, you may have little existing credit to lose. But the program still requires you to stop using the plan for Imvexxy for the rest of the calendar year—even if an appeal succeeds or benefits change. That is why the order matters: identify the door, get the written decision, get the live program quote, then choose.

→ Before you submit the program form, ask your plan or a free SHIP counselor to review the TrOOP consequence with the rest of your medication list.

Is there a generic for Imvexxy in 2026?

Yes, FDA approved the first generic version of Imvexxy on December 8, 2025, in 4 mcg and 10 mcg strengths and described it as bioequivalent to the brand. What we could not verify on August 28, 2026 was commercial launch or pharmacy stock. FDA approval means the product may be marketed; it does not prove a pharmacy can order it today.

FDA’s announcement is unambiguous: the first generic estradiol vaginal inserts referencing Imvexxy were approved December 8, 2025, in the same two strengths.^[16]

The market-status answer is less satisfying. FDA’s Paragraph IV Certifications List dated August 17, 2026 shows the Imvexxy generic’s first-applicant approval date, but the “date of first commercial marketing” field is blank.^[17]

So the accurate line is:

FDA-approved generic; commercial launch and pharmacy availability not verified as of August 28, 2026.

Not “there is no generic.” Not “the generic is on shelves.” Both statements go beyond the record.

The name trap: not every “estradiol vaginal insert” is generic Imvexxy

A widely marketed 10 mcg product is also labeled estradiol vaginal inserts. That product references Vagifem, uses an applicator, and is labeled for atrophic vaginitis due to menopause. It is not the newly approved generic of Imvexxy, which references Imvexxy and comes in 4 mcg and 10 mcg strengths.^[18]

That means your pharmacist cannot treat the familiar generic Vagifem product as an automatic generic substitution for Imvexxy. Moving to it requires a new prescription and a prescriber’s clinical decision.

When you call the pharmacy, ask two separate questions:

1. 1. “Can your wholesaler order the FDA-approved generic that references Imvexxy in my strength?”
2. 2. “Are you instead quoting the 10 mcg generic that references Vagifem?”

One sentence prevents a very expensive misunderstanding.

Which vaginal estrogen alternatives do Medicare formularies list?

Generic estradiol vaginal cream and generic 10 mcg vaginal inserts appeared on substantially more listings in the July 2026 exact-NDC comparison, and current carrier examples place them on lower tiers than Imvexxy. They remain different FDA-approved products with different forms, directions, labeled uses, and handling. A formulary preference is not a claim of clinical equivalence.

Product	Current FDA-labeled use summarized	Form and practical difference	July 2026 exact-NDC listing breadth from the comparison
Imvexxy 4 or 10 mcg	Moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause	Softgel insert placed manually; 18-count starter and 8-count maintenance cartons	1 PDP / 37 MA-PD listings per displayed pack
Generic estradiol 10 mcg vaginal inserts / Yuvafem-type product	Atrophic vaginitis due to menopause	Tablet-style insert administered with an applicator; one marketed strength	Generic row 32 / 292; Yuvafem 31 / 282
Generic estradiol vaginal cream 0.01%	Moderate-to-severe symptoms of vulvar and vaginal atrophy due to menopause	Measured cream dose and applicator; dosing differs from inserts	35 / 295
Premarin Vaginal Cream	Atrophic vaginitis and kraurosis vulvae; also moderate-to-severe dyspareunia due to menopause	Conjugated-estrogen cream, not estradiol; no generic equivalent shown here	28 / 240
Estring	Moderate-to-severe symptoms of vulvar and vaginal atrophy due to menopause	Vaginal ring worn for 90 days	18 / 84

The FDA labels support the product descriptions; the Q1Medicare index supports only the listing-breadth column.^{[8][18][19][20][21]}

The strongest insurance pattern is not subtle. In Humana’s specific Group Plus 26800 list, estradiol vaginal cream and Yuvafem are Tier 1, Premarin Vaginal Cream is Tier 2, and Imvexxy Maintenance Pack is Tier 3 with prior authorization.^[6]

That is a clean prescriber conversation:

“My plan lists these local vaginal-estrogen options. Which, if any, is clinically appropriate for me, and what would I give up by switching from Imvexxy?”

The honest counterweight

Sometimes a listed alternative does not fit, is hard to use, causes a problem, or fails after an adequate trial. That is not an argument to pretend the products are equivalent. It is evidence your prescriber can use in an exception request.

One anonymous Drugs.com reviewer described the coverage cliff in a sentence: “Then I turned 65, and Medicare/Blue Cross entered my life.” She reported that Imvexxy had worked for her, that coverage and price changed, and that the replacement did not work for her. That is one patient, one plan, and a 2020 review—not proof of efficacy or a national coverage rule.^[22]

We kept that quote because it captures the actual fear behind this search: not merely paying more, but being forced away from something that is working.

If that is your situation, do not hide it inside “patient prefers brand.” Your prescriber’s statement should document the product tried, duration, response, adverse effect or practical barrier, and why Imvexxy is medically necessary for you.

→ Compare local vaginal estrogen options side by side — forms, labeled uses, dosing patterns, and the questions to take to your prescriber.

How do you request an exception or appeal an Imvexxy denial?

Match the request to the plan’s actual decision. Prior authorization and formulary exceptions need prescriber evidence. An “excluded” or “not a Part D drug” answer needs a formal written coverage determination so the plan must state its basis and give you redetermination instructions. Medicare recognizes five appeal levels if you keep receiving unfavorable decisions.

Door 1: covered, but restricted

If the plan requires prior authorization, step therapy, or a quantity limit, ask which exact information is missing. Your prescriber may request that the utilization-management requirement be waived when the covered alternative would not be as effective, would cause adverse effects, or the requested drug is otherwise medically necessary under the plan’s rules.^[7]

A tiering exception asks the plan to apply lower cost-sharing terms to a non-preferred drug. Not every drug or tier is eligible, so ask your plan before building the case around it.

Door 2: not on the formulary

A formulary exception is the correct request for a Part D drug that is not on the plan’s formulary. CMS requires the prescriber’s supporting statement. The exception clock begins after the plan receives it—not when you first call.^[7]

Once the supporting statement arrives, the plan must provide notice within:

• 72 hours for a standard exception request; or
• 24 hours for an expedited request when the expedited standard is met.^[7]

Do not merely ask the office to “appeal it.” Ask:

• Who is completing the supporting statement?
• When was it sent?
• To which fax or portal?
• What confirmation number proves the plan received it?

Door 3: the plan says “excluded” or “not a Part D drug”

This is where the original draft would have sent you away from appeals. That would have been the wrong move.

Request a formal coverage determination and say:

“My prescription is for Imvexxy for its FDA-labeled use: moderate-to-severe dyspareunia due to menopause. A May 10, 2018 ISSWSH announcement reports that CMS clarified these drugs are not excluded from Part D when used consistently with that labeling. Please issue the plan’s coverage determination and the written basis for any unfavorable decision.”

A standard non-exception benefit determination is generally due within 72 hours; an expedited one within 24 hours. If it is unfavorable, CMS says the notice must contain the information required to request redetermination.^[4]

Medicare describes five levels of appeal. Level 1 is redetermination by the plan; later levels can move outside the plan.^[23]

This does not guarantee you win. It guarantees the plan has to turn a vague sentence into a decision you can examine and challenge.

What makes the prescriber statement useful

The statement should be specific enough that a reviewer can see your case rather than a template:

• exact diagnosis and labeled use;
• exact Imvexxy strength and package;
• covered alternatives tried, including dates when available;
• response, adverse effects, contraindications, or practical barriers;
• why the preferred alternatives are not expected to be as effective or may cause adverse effects; and
• why the requested product is medically necessary.

Get a copy. Do not let the only version of your case live in a fax queue you cannot see.

Ask about a transition fill—do not assume one is automatic

When you are new to a plan or the formulary changes, ask whether you qualify for a temporary transition supply while the exception is reviewed. Eligibility and timing depend on the plan and your situation. Use it as a bridge, not as a substitute for filing the request.

What exactly should you say to the plan, pharmacy, and prescriber?

The scripts below keep each person from answering a broader question than the one you asked. Read the exact pack, ask for the exact decision, and end every denial call by requesting the written process that turns the answer into something reviewable.

Say this to the plan

“I am checking current 2026 coverage for Imvexxy. My prescription is for [4 mcg / 10 mcg], the [18-count starter / 8-count maintenance] pack. Is that exact product on my formulary? What tier is it, does my deductible apply, and are there prior authorization, step-therapy, or quantity-limit requirements? If it is not covered, is it non-formulary or are you classifying it as excluded or not a Part D drug? Please tell me how to request the formal coverage determination or exception in writing.”

Say this to the pharmacy

“Please run a live claim on my exact prescription. What 11-digit NDC are you billing, what quantity and days’ supply did you enter, what is the full rejection code, what did the plan pay, and what would I owe? Is this pharmacy preferred under my plan? Can you check whether the plan recognizes another public package code for this Imvexxy pack?”

Say this to the prescriber’s office

“My plan classified the claim as [prior authorization / non-formulary / excluded]. I have the plan form, fax or portal, and reference number. Will the prescriber submit a supporting statement that documents what I have tried, what happened, why the covered options are not suitable for me, and why this exact Imvexxy prescription is medically necessary? Please send me a copy and the submission confirmation.”

Free help exists. Your State Health Insurance Assistance Program—SHIP—offers individualized, unbiased Medicare counseling. Medicare says SHIP can help review coverage and costs, Extra Help, and appeals. You can also call 1-800-MEDICARE.^[24]

Do Extra Help, Part B, or the Medicare Prescription Payment Plan change the answer?

Extra Help can sharply reduce costs for a drug your plan covers, but it does not force a plan to add Imvexxy to its formulary. A routine self-administered Imvexxy pharmacy fill is not a standard Part B benefit. The Medicare Prescription Payment Plan can spread plan-covered out-of-pocket costs through the calendar year, but it does not lower the total.

Extra Help in 2026

For eligible people in 2026, Medicare lists a $0 plan premium and $0 deductible under Extra Help, with copays of no more than $5.10 for each generic and $12.65 for each brand-name covered drug at participating pharmacies. Medicare lists annual income and resource limits of $23,940 and $18,090 for an individual, and $32,460 and $36,100 for a married couple; some people qualify automatically and others can apply.^[25]

Apply rather than disqualifying yourself from memory. The limits change, and Medicare says some income and resources do not count.

Extra Help still works through Part D coverage. It can reduce the price of covered Imvexxy after the plan approves it; it does not turn a non-formulary drug into a covered one by itself.

Medicare also says Extra Help is not available in Puerto Rico, the U.S. Virgin Islands, Guam, the Northern Mariana Islands, or American Samoa. The separate Mayne program states that eligible participants can reside in Puerto Rico, Guam, and the U.S. Virgin Islands, subject to its terms.^[14][25]

Part B

Part B covers certain drugs in defined circumstances, including many products administered in a clinical setting. Imvexxy is prescribed for the patient to obtain and use herself. A normal retail-pharmacy fill therefore belongs in the Part D or MA-PD conversation, not a routine Part B claim.

Medicare Prescription Payment Plan

This plan option can make a large covered-drug bill easier to schedule across the calendar year. It does not reduce the total, and it applies to out-of-pocket costs for drugs covered by your Medicare drug plan.^[10]

It can help when the problem is cash flow. It cannot solve non-formulary status, an exclusion classification, or the loss of TrOOP credit under the Mayne alternative coupon.

Is Imvexxy worth fighting your plan for?

That depends on what Imvexxy is doing for you, what you have already tried, and how much effort or cost the plan route demands. The pivotal trial showed statistically significant improvement, but the advantage over placebo on the symptom-severity measure was modest: about 0.24 points for 4 mcg and 0.41 points for 10 mcg on the study’s four-category scale. We are printing the placebo result because you deserve the whole comparison.

The current FDA label describes one 12-week randomized, double-blind, placebo-controlled trial with 574 postmenopausal women, ages 40 to 75, with a mean age of 59.^[1]

Week-12 least-square mean change in dyspareunia severity	Result
Imvexxy 4 mcg	−1.52
Imvexxy 10 mcg	−1.69
Placebo	−1.28
Difference versus placebo, calculated from label values	4 mcg: −0.24 · 10 mcg: −0.41

The 4 mcg comparison was statistically significant at p=0.0149; the 10 mcg comparison was p<0.0001.^[1]

Most marketing summaries print the treatment changes and let the placebo column disappear. We are not doing that. You are deciding whether to file paperwork, pay outside insurance, or change something that may already be working. The comparison group belongs in the decision.

What the label says about adverse reactions and absorption

The only treatment-emergent adverse reaction reported at 3% or more and numerically more often than placebo in the trial table was headache: 3.7% with 4 mcg, 2.6% with 10 mcg, and 3.1% with placebo.^[1]

In a 54-woman pharmacokinetic substudy, average estradiol concentration after 14 daily doses was 3.6 pg/mL with 4 mcg, 4.6 pg/mL with 10 mcg, and 4.3 pg/mL with placebo. The label cautions that serum estrogen concentrations do not predict an individual woman’s response or risk.^[1]

Do not turn those group averages into a personal safety guarantee. They are useful context, not a substitute for your medical history.

What about the boxed warning?

The Imvexxy DailyMed label we checked still contains the established estrogen boxed warning. FDA announced labeling changes for menopausal hormone therapy products in February 2026, and its initial updated-product list included Estring but not Imvexxy.^[26][27]

That is a label-update status, not a ranking of one vaginal product as safer than another. Use the current Imvexxy prescribing information and your clinician’s assessment—not the timing of an administrative update—to discuss contraindications and risk.

What does the label say about women over 65?

The label states that clinical studies did not include enough women over 65 to determine whether their responses differ from those of younger participants.^[1]

That does not say women over 65 cannot use Imvexxy. It says the age-specific evidence was limited. Bring that line to the prescriber who knows your history instead of letting a coverage representative turn it into a clinical verdict. Nobody gets to turn “evidence was limited” into “you are too old for treatment.”

The decision

If Imvexxy is working and a covered alternative has failed, caused a problem, or is not suitable for you, there is a real reason to push—and a stronger exception record to build.

If you have not tried a covered option and your prescriber considers one appropriate, that route may be faster and cheaper. Trying it is not surrender. It also creates concrete evidence if it does not fit.

Either way, the next clinical decision belongs with a prescriber.

What can you do if your prescriber is booked for weeks?

A cash-pay telehealth visit may get you access to a prescriber where available, but it cannot make Medicare cover Imvexxy. The visit can address a new prescription, an alternative, or supporting documentation only if the clinician decides it is medically appropriate. Your existing clinician is usually the cleanest first route because that office already has your treatment history.

Send your clinician a portal message containing:

• your exact strength and pack;
• the pharmacy rejection code;
• the plan’s classification—covered with restriction, non-formulary, or excluded;
• the exception or determination form and submission route;
• what you have tried and what happened; and
• the deadline for a standard or expedited decision.

That is a better message than “insurance denied it—please help.” You have already done the administrative half.

The honest limitation before the sponsored option

Sesame is cash pay. It does not accept Medicare, Medicaid, or third-party insurance, and a visit through Sesame does not change what your drug plan covers. Provider availability is not guaranteed, and prescriptions are issued only when the independent clinician determines they are medically necessary.^[28]

The value is narrower: where a suitable clinician is available, it may provide another route to a prescriber conversation without waiting for an insurance-billed appointment. Waiting weeks for the conversation is its own cost. That clinician may decide to discuss the existing prescription, a formulary alternative, or documentation. Nothing is guaranteed, and the medication remains a separate pharmacy expense.

→ Check current cash-pay visit options available through Sesame (sponsored)

If your own clinician can handle the form, stay there. The office that knows what worked, what failed, and why is often best positioned to write the statement your plan needs.

When can you change Medicare plans for better Imvexxy coverage?

Medicare Open Enrollment runs October 15 through December 7, with the selected coverage beginning January 1. That is the annual window to compare next year’s formularies, but it is not the only possible enrollment opportunity; Special Enrollment Periods and the Medicare Advantage Open Enrollment Period may apply in specific situations.

Before choosing a plan:

1. 1. Enter every prescription—not just Imvexxy—into Medicare Plan Finder.
2. 2. Check the exact Imvexxy strength and both starter and maintenance packages.
3. 3. Check tier, prior authorization, quantity limit, pharmacy network, deductible, and estimated annual cost.
4. 4. Save or print the formulary evidence with its date.
5. 5. Call the plan and ask whether the exact package will be covered on January 1.

A plan can change formularies from year to year. The UnitedHealthcare 2026 notice is proof that last year’s answer does not buy next year’s refill.^[5]

If you use Mayne’s alternative coupon, its approval lasts only through the end of the calendar year in which enrollment was approved. Do not assume next year’s thresholds, terms, or approval will be identical; re-check the program before January.^[14]

Medicare’s annual Open Enrollment dates are October 15–December 7.^[29]

What did The HRT Index actually verify?

We opened the current program terms, the opt-out letter, the current Imvexxy label, FDA’s generic records, Medicare’s 2026 cost and appeal pages, two scoped carrier documents, and exact-NDC index rows. We did not run your claim, enroll in the coupon, call your plan, submit an appeal, or confirm a generic package in pharmacy stock. The page says where the record ends.

Evidence checked on or re-checked for August 28, 2026	What it establishes	What it cannot establish
Current Imvexxy DailyMed label	Approved use, dosing, strengths, carton sizes, warnings, trial results, adverse-reaction table, pharmacokinetic table, geriatric limitation, one public NDC family	Your clinical fit, current plan coverage, or pharmacy stock
Second public Imvexxy DailyMed record	The 68308 code family exists in public labeling records	Which code your pharmacy will bill today or whether a code mismatch caused a denial
Mayne standard copay-card PDF	Commercial-insurance requirement, Medicare/cash exclusions, no fixed copay, PA/deductible conditions, Dec. 31, 2026 expiration	Your eligibility or final card price
Mayne Medicare Part D Alternative Coupon page and opt-out letter	Pack-level eligibility thresholds, rest-of-year opt-out, plan notification, no TrOOP credit, data handling, participating-pharmacy and reimbursement limits	The final price the program will quote you
Medicare.gov 2026 Part D costs	$615 maximum deductible, standard 25% initial-stage share, $2,100 covered-drug out-of-pocket cap, $0 after the cap	Your plan’s exact tier/copay or live pharmacy price
CMS coverage-determination and exception pages	What can be challenged, prescriber-statement requirement, 72/24-hour decision timeframes, redetermination path	Whether your individual request will be approved
U.S. Code and ISSWSH May 10, 2018 announcement	Statutory exclusion language and the reported CMS clarification for labeled menopause-related dyspareunia drugs	The underlying CMS clarification memo, which we did not locate
UnitedHealthcare 2026 notice	Imvexxy non-formulary within the notice’s stated plan scope and its named alternatives	Coverage under every UnitedHealthcare plan
Humana Group Plus Formulary 26800 list	Imvexxy Maintenance Pack Tier 3 with PA in that specific group formulary; lower tiers for several alternatives	Coverage under every Humana plan or the complete formulary
Q1Medicare July 2026 exact-NDC index	Reproducible comparative listing counts and the 24-unit data discrepancy	A national coverage percentage, local guarantee, enrollment-weighted rate, clinical equivalence, or plan motive
FDA generic announcement and Aug. 17 Paragraph IV list	First generic approval Dec. 8, 2025; 4 and 10 mcg; bioequivalence; blank first-commercial-marketing field in that list	Current wholesaler inventory or pharmacy availability
SingleCare and Drugs.com price pages	Dated cash and discount snapshots that demonstrate price dispersion	Your Medicare copay or a guaranteed cash price

This page was produced under The HRT Index Verification Standard: read every published price, keep FDA-approved and compounded options separate, verify state availability and insurance, and re-check on a fixed schedule—top providers monthly and the full roster quarterly. This article discusses FDA-approved prescription products only; it does not present a compounded medication as equivalent to an FDA-approved product.

Recency plan for this page

Element that can go stale	Refresh cadence	Re-verification trigger and method
Standard copay-card terms and expiration	Monthly	Open the official PDF; compare eligibility, exclusions, limits, and expiration
Medicare alternative-coupon thresholds and opt-out terms	Monthly	Re-read official form and letter; archive dated copies
Medicare Part D deductible and out-of-pocket cap	Annually, with fall preview	Check Medicare.gov for the new benefit year
UnitedHealthcare/Humana examples	Quarterly; monthly during fall enrollment	Open the exact carrier document and confirm scope, year, tier, and restrictions
Generic approval and market status	Monthly	Check FDA records, DailyMed, wholesaler/pharmacy availability, and the first-commercial-marketing field
Cash-price snapshots	Monthly	Record package, strength, ZIP/pharmacy when supplied, source, and date
NDCs and carton sizes	Quarterly and on label change	Compare current DailyMed records with the live pharmacy-billed NDC
Appeal timeframes and forms	Quarterly	Check current CMS and Medicare appeal pages
Sesame insurance and service terms	Monthly while the sponsored link is live	Re-read official terms and self-pay agreement

Found something that changed? Tell us—and do not send your Medicare number, plan member ID, date of birth, prescription image, or medical records.

What is the bottom line on Medicare coverage for Imvexxy?

Medicare can cover Imvexxy, but your route depends on the plan’s exact decision. Covered-with-a-hurdle calls for authorization or a restriction request. Non-formulary calls for an exception. “Excluded” calls for a formal written determination and, if unfavorable, an appeal—not surrender. The separate Medicare coupon belongs after you understand its threshold, actual price, and rest-of-year TrOOP trade-off.

Here is the whole page reduced to seven decisions:

1. 1. Confirm that you have Part D or Medicare Advantage drug coverage. Original Medicare Parts A and B do not pay for a routine Imvexxy pharmacy fill.
2. 2. Check the exact product. Strength, starter versus maintenance pack, quantity, days’ supply, and NDC all matter.
3. 3. Force “not covered” into one of three doors. Covered with a restriction, non-formulary, or classified as excluded/not a Part D drug.
4. 4. Use the matching request. Prior authorization or restriction exception for Door 1, formulary exception for Door 2, formal coverage determination and appeal path for Door 3.
5. 5. Do not use the standard commercial card with Medicare. It excludes Medicare and does not promise a fixed copay.
6. 6. Treat the Mayne Medicare figures as eligibility thresholds, not prices. Get the actual program quote and price the loss of TrOOP credit before enrolling.
7. 7. Ask about the FDA-approved generic, but verify stock. Approval is confirmed; commercial availability was not confirmed on August 28, 2026.

You do not need another generic search result. You need the exact claim, the exact denial reason, and the exact next request.

For the broader coverage picture, see Does Medicare cover HRT for menopause?.

Frequently asked questions

Does Medicare Part D cover Imvexxy in 2026?

Some Part D and Medicare Advantage drug plans cover Imvexxy, while others do not. A specific Humana 2026 group formulary lists the maintenance pack on Tier 3 with prior authorization, while a UnitedHealthcare 2026 notice makes Imvexxy non-formulary within its stated plan scope. Check your exact pack under your exact plan.^[5][6]

Does Medicare Advantage cover Imvexxy?

It can. Only Medicare Advantage plans that include prescription coverage—MA-PD plans—can cover a routine Imvexxy pharmacy fill, and each plan uses its own formulary, tier, pharmacy network, and restrictions.

Does Original Medicare cover Imvexxy?

Original Medicare Parts A and B do not include ordinary outpatient prescription-drug coverage. A routine self-administered Imvexxy pharmacy fill is normally handled through Part D or a Medicare Advantage plan with drug coverage.

Why did the Imvexxy savings card stop working after I became Medicare-eligible?

The current standard card excludes Medicare, Medicare Advantage, Part D, Medigap, and certain Medicare-eligible people with employer or retiree prescription benefits. It also excludes cash-paying patients. Ask the pharmacy for the rejection reason rather than assuming age alone triggered it.^[13]

Can I use the regular Imvexxy copay card with commercial insurance?

Potentially, but only when you meet the card terms and your commercial or Marketplace plan covers the valid Imvexxy prescription at the fill. The current card does not promise a fixed copay; deductible, prior authorization, reimbursement limits, and other restrictions can still apply.^[13]

How much is Imvexxy without insurance?

Dated August 2026 sources disagree. Drugs.com displayed roughly $218.54–$234.38 for an 8-insert maintenance pack, depending on strength, while a SingleCare article used a $319 maintenance benchmark and showed a $184 coupon example at one Kroger context. Get a same-day quote for your exact pack, pharmacy, and ZIP.^[11][12]

What are the $50, $100, and $150 Medicare coupon amounts?

They are pack-specific eligibility thresholds, not guaranteed final prices. The program may apply if the plan does not cover Imvexxy or your plan out-of-pocket amount exceeds the stated threshold; the program and participating pharmacy must tell you the actual price.^[14]

Does spending through the Mayne Medicare coupon count toward the $2,100 Part D cap?

No. The terms require participants not to seek true out-of-pocket credit for Imvexxy purchases made through the program, and the opt-out letter says those purchases will not count toward TrOOP.^[14][15]

Is there a generic for Imvexxy?

FDA approved the first generic on December 8, 2025 in 4 mcg and 10 mcg strengths and described it as bioequivalent to Imvexxy. Commercial launch and pharmacy stock were not verified as of August 28, 2026; FDA’s August 17 Paragraph IV list left the first-commercial-marketing field blank.^[16][17]

Are generic 10 mcg estradiol vaginal inserts the generic of Imvexxy?

The widely marketed 10 mcg generic vaginal insert is a generic of Vagifem, not Imvexxy. It has a different reference product, administration system, strength range, and labeled use. Switching requires a new prescription and a prescriber’s decision.^[18]

Can the pharmacy substitute a generic for Imvexxy automatically?

Only an actually marketed, substitutable generic referencing Imvexxy could enter that normal substitution path under applicable state law and pharmacy rules. The familiar generic Vagifem-type 10 mcg insert is a different product and cannot be treated as generic Imvexxy.

What if my plan covers the maintenance pack but not the starter pack?

Ask the plan to check the exact strength, carton, NDC, quantity, and days’ supply for both. Starter and maintenance packages are separate claim records. Do not change the labeled schedule or package without the prescriber.

Can I appeal if the plan says Imvexxy is excluded from Part D?

Ask for a formal written coverage determination. The 2018 CMS clarification reported by ISSWSH says menopause-related dyspareunia drugs are not excluded when used consistently with that labeling, and CMS says an unfavorable coverage determination must provide redetermination instructions.^[2][4]

How long does an Imvexxy formulary exception take?

After the plan receives the prescriber’s supporting statement, CMS requires a decision within 72 hours for a standard exception or 24 hours for an expedited request when the expedited standard is met.^[7]

Can a discount card be cheaper than Medicare?

It can be cheaper for one fill, but it is used outside the plan rather than combined with the same Part D claim. Spending outside Part D generally does not count toward the plan’s out-of-pocket cap, so compare the calendar-year effect rather than one receipt.

Does Extra Help cover Imvexxy?

Extra Help can reduce the price when your Part D or MA-PD plan covers Imvexxy. It does not force a non-formulary drug onto the plan’s list or replace the exception process.^[25]

Does Medicare Part B cover Imvexxy?

Not as a routine retail-pharmacy prescription for self-administration. The relevant Medicare drug-coverage route is Part D or a Medicare Advantage plan that includes prescription coverage.

What should I do if I have bleeding after menopause?

Contact a clinician. The current Imvexxy label lists undiagnosed abnormal genital bleeding as a contraindication and calls for diagnostic evaluation of persistent or recurring postmenopausal bleeding. Do not let a coverage problem delay that evaluation.^[1]

---

Not affiliated with or endorsed by Medicare, CMS, Mayne Pharma, Humana, UnitedHealthcare, FDA, or the U.S. government. Educational content only—not medical advice and not medically reviewed by a clinician. Imvexxy and every medication compared on this page are FDA-approved prescription products; this page does not describe a compounded medication as equivalent to an FDA-approved product.

Still not sure which HRT program is right for you? Take our free 90-second matching quiz.

→ Start Find My HRT Path

---

¹ U.S. National Library of Medicine, DailyMed, Imvexxy (estradiol vaginal inserts) prescribing information, set ID 104be9f2-a8f6-430e-9e01-2ee7cc1861f1. Checked August 28, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=104be9f2-a8f6-430e-9e01-2ee7cc1861f1

² International Society for the Study of Women’s Sexual Health, Dyspareunia: CMS Clarification Results in Expanded Treatment and Coverage Under Medicare Part D, May 10, 2018. https://www.isswsh.org/news/259-dyspareunia-cms-clarification-results-in-expanded-treatment-and-coverage-under-medicare-part-d

³ U.S. House of Representatives, Office of the Law Revision Counsel, 42 U.S.C. § 1395w-102(e)(2)(A), Covered Part D Drug. Checked August 28, 2026. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1395w-102&num=0&edition=prelim

⁴ Centers for Medicare & Medicaid Services, Coverage Determinations. Checked August 28, 2026. https://www.cms.gov/medicare/appeals-grievances/prescription-drug/coverage-determinations

⁵ UnitedHealthcare, Important changes to Medicare Advantage and Part D prescription drug plans, December 1, 2025. https://www.uhcprovider.com/en/resource-library/news/2025/ma-part-d-plan-changes.html

⁶ Humana, 2026 Commonly Prescribed Medications List—Group Plus Formulary 26800, page 7. Checked August 28, 2026. https://assets.humana.com/is/content/humana/26800pdf

⁷ Centers for Medicare & Medicaid Services, Exceptions. Checked August 28, 2026. https://www.cms.gov/medicare/appeals-grievances/prescription-drug/exceptions

⁸ Q1Medicare, 2026 Medicare Part D formulary index by exact drug/NDC, July 2026 data as displayed with the finder configured to ZIP 33142. Checked August 28, 2026. Imvexxy: https://q1medicare.com/PartD-2026-SearchPDPDrugFinderByLetter.php?ded=&defaultState=1&gap=&letter=I&planType=&plans=&plans2=&prem=&sort=&stateReg=11FL&zip=33142&zipCountyCode=12086 ; estradiol/Estring/Estrace: https://q1medicare.com/PartD-2026-SearchPDPDrugFinderByLetter.php?ded=&defaultState=1&gap=&letter=E&planType=&plans=&plans2=&prem=&sort=&stateReg=11FL&zip=33142&zipCountyCode=12086 ; Premarin: https://q1medicare.com/PartD-2026-SearchPDPDrugFinderByLetter.php?ded=&defaultState=1&gap=&letter=P&planType=&plans=&plans2=&prem=&sort=&stateReg=11FL&zip=33142&zipCountyCode=12086 ; Yuvafem: https://q1medicare.com/PartD-2026-SearchPDPDrugFinderByLetter.php?ded=&defaultState=1&gap=&letter=Y&planType=&plans=&plans2=&prem=&sort=&stateReg=11FL&zip=33142&zipCountyCode=12086

⁹ U.S. National Library of Medicine, DailyMed, Imvexxy label record, set ID 6ce645c0-a550-4ae9-8dbd-3853ee8b7d26. Checked August 28, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ce645c0-a550-4ae9-8dbd-3853ee8b7d26

¹⁰ Medicare.gov, How much does Medicare drug coverage cost? and Medicare Prescription Payment Plan. Checked August 28, 2026. https://www.medicare.gov/health-drug-plans/part-d/basics/costs and https://www.medicare.gov/prescription-payment-plan

¹¹ SingleCare, Imvexxy without insurance: Cost and savings, updated August 6, 2026. Price examples shown for ZIP 23666 when checked. https://www.singlecare.com/blog/imvexxy-without-insurance/

¹² Drugs.com, Imvexxy Prices, Coupons, Copay Cards and Patient Assistance. Checked August 28, 2026. https://www.drugs.com/price-guide/imvexxy

¹³ Mayne Pharma, Imvexxy Copay Card—Program Terms, Conditions, and Eligibility Criteria, material code PM-US-IVXY-0044 09/26. Checked August 28, 2026. https://www.imvexxy.com/wp-content/uploads/2025/07/MAYNE_Imvexxy_Copay-Card_091125_NEW_5.pdf

¹⁴ Mayne Pharma, Imvexxy Medicare Part D Alternative Coupon Program—Eligibility Criteria, Terms and Conditions. Checked August 28, 2026. https://maynepharmacoupon.com/imvexxy-form

¹⁵ Mayne Pharma, Imvexxy Medicare Part D Alternative Coupon Program Opt Out Letter to Health Plan, 2026. https://maynepharmacoupon.com/imvexxy-letter.pdf

¹⁶ U.S. Food and Drug Administration, FDA Approves First Generic Estradiol Vaginal Insert for Treatment of Moderate to Severe Dyspareunia, December 8, 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-generic-estradiol-vaginal-insert-treatment-moderate-severe-dyspareunia

¹⁷ U.S. Food and Drug Administration, Paragraph IV Certifications List, dated August 17, 2026, Imvexxy row on page 33. https://www.fda.gov/media/166048/download

¹⁸ U.S. National Library of Medicine, DailyMed, Estradiol vaginal inserts, 10 mcg, set ID 8cb31c7c-fba8-4201-833d-844ea1a8a4de. Checked August 28, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8cb31c7c-fba8-4201-833d-844ea1a8a4de

¹⁹ U.S. National Library of Medicine, DailyMed, Estradiol vaginal cream 0.01% prescribing information. Checked August 28, 2026. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c94738ff-dece-4fb6-bb44-4f8832a45f38&type=display

²⁰ U.S. National Library of Medicine, DailyMed, Premarin Vaginal Cream prescribing information. Checked August 28, 2026. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5&type=display

²¹ U.S. National Library of Medicine, DailyMed, Estring prescribing information. Checked August 28, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=110b9865-5a07-4d45-b560-e89947f12600

²² Drugs.com, Imvexxy user reviews, anonymous review dated October 21, 2020. Checked August 28, 2026. User reports are personal experiences, not evidence of typical results, safety, or efficacy. https://www.drugs.com/comments/estradiol-topical/imvexxy.html

²³ Medicare.gov, Appeals in a Medicare drug plan. Checked August 28, 2026. https://www.medicare.gov/providers-services/claims-appeals-complaints/appeals/drug-plans

²⁴ Medicare.gov, Talk to someone—SHIP and 1-800-MEDICARE. Checked August 28, 2026. https://www.medicare.gov/talk-to-someone

²⁵ Medicare.gov, Help with drug costs—Extra Help, 2026 figures. Checked August 28, 2026. https://www.medicare.gov/basics/costs/help/drug-costs

²⁶ U.S. Food and Drug Administration, FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, February 12, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

²⁷ U.S. Food and Drug Administration, Menopausal Hormone Therapies with Updated Prescribing Information. Checked August 28, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information

²⁸ Sesame, Terms of Service and Patient Self-Pay Agreement. Checked August 28, 2026. https://sesamecare.com/terms-of-service and https://sesamecare.com/patient-self-pay-agreement

²⁹ Medicare.gov, Medicare Open Enrollment. Checked August 28, 2026. https://www.medicare.gov/health-drug-plans/open-enrollment